|
Gene: CCDC170 |
Gene summary for CCDC170 |
Gene summary. |
Gene information | Species | Human | Gene symbol | CCDC170 | Gene ID | 80129 |
Gene name | coiled-coil domain containing 170 | |
Gene Alias | C6orf97 | |
Cytomap | 6q25.1 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q8IYT3 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
80129 | CCDC170 | HCC2_Meng | Human | Liver | HCC | 2.39e-03 | 3.67e-02 | 0.0107 |
80129 | CCDC170 | HCC1 | Human | Liver | HCC | 6.31e-22 | 4.37e+00 | 0.5336 |
80129 | CCDC170 | HCC2 | Human | Liver | HCC | 3.91e-14 | 1.41e+00 | 0.5341 |
80129 | CCDC170 | HCC5 | Human | Liver | HCC | 3.79e-21 | 2.82e+00 | 0.4932 |
80129 | CCDC170 | S014 | Human | Liver | HCC | 2.09e-06 | 2.30e-01 | 0.2254 |
80129 | CCDC170 | S015 | Human | Liver | HCC | 2.71e-07 | 2.59e-01 | 0.2375 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CCDC170 | SNV | Missense_Mutation | c.82G>T | p.Val28Phe | p.V28F | Q8IYT3 | protein_coding | tolerated(0.09) | possibly_damaging(0.61) | TCGA-21-5787-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | |
CCDC170 | SNV | Missense_Mutation | novel | c.916G>A | p.Glu306Lys | p.E306K | Q8IYT3 | protein_coding | deleterious(0.02) | benign(0.076) | TCGA-22-1002-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CCDC170 | SNV | Missense_Mutation | c.1377C>A | p.Asp459Glu | p.D459E | Q8IYT3 | protein_coding | tolerated(0.21) | benign(0.029) | TCGA-22-5481-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
CCDC170 | SNV | Missense_Mutation | c.1405N>T | p.Val469Phe | p.V469F | Q8IYT3 | protein_coding | deleterious(0) | possibly_damaging(0.576) | TCGA-33-4533-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CCDC170 | SNV | Missense_Mutation | c.1984G>T | p.Gly662Cys | p.G662C | Q8IYT3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-33-4566-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
CCDC170 | SNV | Missense_Mutation | c.399N>A | p.Asn133Lys | p.N133K | Q8IYT3 | protein_coding | deleterious(0.03) | probably_damaging(0.987) | TCGA-34-5231-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
CCDC170 | SNV | Missense_Mutation | c.2101N>G | p.Thr701Ala | p.T701A | Q8IYT3 | protein_coding | tolerated(0.73) | benign(0.003) | TCGA-34-5236-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
CCDC170 | SNV | Missense_Mutation | novel | c.1562N>T | p.Arg521Leu | p.R521L | Q8IYT3 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-34-8454-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
CCDC170 | SNV | Missense_Mutation | c.1342N>T | p.Met448Leu | p.M448L | Q8IYT3 | protein_coding | tolerated(0.36) | benign(0.017) | TCGA-39-5024-01 | Lung | lung squamous cell carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | SD | |
CCDC170 | SNV | Missense_Mutation | c.215C>T | p.Ser72Phe | p.S72F | Q8IYT3 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-43-3920-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |